Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec 30;15(1):30.
doi: 10.3390/toxins15010030.

Real-Time Documentation of the Effect of Onabotulinumtoxin A Detrusor Injection in OAB Patients-Preliminary Results

Heinrich Schulte-Baukloh  1 , Catarina Weiß  2 , Sarah Weinberger  1 , Mandy Hubatsch  1 , Thorsten Schlomm  1 , Bernhard Ralla  1
Affiliations

Real-Time Documentation of the Effect of Onabotulinumtoxin A Detrusor Injection in OAB Patients-Preliminary Results

Heinrich Schulte-Baukloh et al. Toxins (Basel). .

Abstract

Introduction: Detrusor injection with onabotulinumtoxin A (OnabotA-DI) is an established therapy for overactive bladder (OAB). Little is known about the exact onset and course of the effect in the days after the injection therapy. By using a new type of app-controlled automated diary pod, for the first time, the precise onset of the effect of OnabotA-DI can be documented in real time. Materials and methods: Patients due for OnabotA-DI were asked to document voiding 3 days before and up to 3 weeks after therapy using the Diary Pod app. The detrusor injection was performed with onabotulinumtoxin A (Botox®), 100 units, at 20 sites of the detrusor muscle in a standardized manner. Voiding on the injection day itself was not documented. Results: A total of 17 patients (15 women, 2 men; aged 33−83 (mean 64.6; median 70) years) were included in the study. The handling of the Diary Pod app was user-friendly, and elderly patients did not encounter technical problems. The results of patients with reliably documented micturitions showed a continuous reduction in micturition frequency every day from the first day and significantly from day 5. For 24 h voiding, from 12.83 ± 5.54 in the 3 days before injection, the following mean values were found with significant (p < 0.05) changes after the intervention: 9.17 ± 3.19 on day 5, 8.75 ± 3.69 on day 10, 7.17 ± 2.04 on day 15, and 5.75 ± 0.5 on day 20. These changes were in similar proportions during the daytime and nighttime. Conclusions: Contrary to previous knowledge, the effect of the OnabotA-DI set in from the first postoperative days and was reflected a similar extent in day and night micturition. This study is the first to document the onset of action of OnabotA-DI in real time.

Keywords: botulinum toxin; injections; intramuscular; overactive bladder; urinary bladder; urinary incontinence.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Graphic representation of the decrease in micturition frequencies in 24 h, before and after injection. The vertical line crosses on the day of injection. The mean value curve is in bold red.
Figure 2
Figure 2
The Diary Pod, an automated bladder diary solution that includes a measuring device connected to a mobile app. The collected data are visualized in a dashboard on the Minze Clinician Portal.
Figure 3
Figure 3
(Left side) Example of documentation of the kind and amount of drinking, micturitions, urgencies, and leakages and (right side) the summaries of these values.
See this image and copyright information in PMC

References

    1. Abrams P., Cardozo L., Fall M., Griffiths D., Rosier P., Ulmsten U., van Kerrebroeck P., Victor A., Wein A. Standardisation Sub-committee of the International Continence Society. The standardisation of terminology of lower urinary tract function: Report from the Standardisation Sub-committee of the International Continence Society. Neurourol. Urodyn. 2002;21:167–178. doi: 10.1002/nau.10052. - DOI - PubMed
    1. Fowler C.J., Auerbach S., Ginsberg D., Hale D., Radziszewski P., Rechberger T., Patel V.D., Zhou J., Thompson C., Kowalski J.W. OnabotulinumtoxinA improves health-related quality of life in patients with urinary incontinence due to idiopathic overactive bladder: A 36-week, double-blind, placebo-controlled, randomized, dose-ranging trial. Eur. Urol. 2012;62:148–157. doi: 10.1016/j.eururo.2012.03.005. - DOI - PubMed
    1. Bientinesi R., Gavi F., Coluzzi S., Nociti V., Marturano M., Sacco E. Neurologic Urinary Incontinence, Lower Urinary Tract Symptoms and Sexual Dysfunctions in Multiple Sclerosis: Expert Opinions Based on the Review of Current Evidences. J. Clin. Med. 2022;11:6572. doi: 10.3390/jcm11216572. - DOI - PMC - PubMed
    1. Chapple C., Sievert K.D., MacDiarmid S., Khullar V., Radziszewski P., Nardo C., Thompson C., Zhou J., Haag-Molkenteller C. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: A randomised, double-blind, placebo-controlled trial. Eur. Urol. 2013;64:249–256. doi: 10.1016/j.eururo.2013.04.001. - DOI - PubMed
    1. Milsom I., Abrams P., Cardozo L., Roberts R.G., Thüroff J., Wein A.J. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 2001;87:760–766. doi: 10.1046/j.1464-410x.2001.02228.x. - DOI - PubMed

Substances